Global Custom Market Research Reports Provider Company

phone

Relmada Therapeutics Inc (RLMD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 14 Jun 2018
  • Number of Pages: 31
  • Category: Company Profile
  • Country: United States of America
Summary

Relmada Therapeutics Inc (Relmada Therapeutics), formerly known as Camp Nine, Inc is a clinical stage specialty pharmaceutical company which develops and commercializes products for the treatment of central nervous system (CNS) diseases. Its product pipeline includes REL-1017 d-Methadone, an antagonist for the treatment of neuropathic pain; REL-1028 BuTab, an oral tablet form of buprenorphine; REL-1015 LevoCap ER, an abuse resistant form of broad spectrum opioid levorphanol; and REL-1021 MepiGel, a topical gel dosage form of local anesthetic mepivacaine. Relmada Therapeutics also develops analgesics and anti-arthritic medicines. Its target treatment areas include chronic pain due to cancer, musculoskeletal disorders and peripheral neuropathy. Relmada Therapeutics is headquartered in New York, the US.

Relmada Therapeutics Inc (RLMD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData


List of Tables 4
List of Figures 4
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Relmada Therapeutics Acquires Global Rights for Dextromethadone 10
Venture Financing 11
Camp Nine Raises USD11 Million in Venture Financing 11
Relmada Therapeutics Raises USD15 Million in Venture Financing 12
Relmada Therapeutics Raises US$8 Million In Series A Venture Financing 13
Relmada Raises US$0.2 Million In Venture Financing 14
Relmada Therapeutics Secures USD3 Million in Series A Funding Round 15
Equity Offering 16
Relmada Therapeutics Raises USD15.2 Million in Private Placement of Shares upon Exercise of Warrants 16
Camp Nine Raises USD2 Million in Private Placement of Shares 17
Debt Offering 18
Relmada Therapeutics to Raise USD6.8 Million in Private Placement of 7% Convertible Promissory Notes Due 2019 18
Acquisition 20
Camp Nine Acquires Relmada Therapeutics 20
Relmada Therapeutics Acquires Medeor 21
Relmada Therapeutics Inc - Key Competitors 22
Relmada Therapeutics Inc - Key Employees 23
Relmada Therapeutics Inc - Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Corporate Communications 25
Jun 28, 2017: Relmada Therapeutics appoints new chair of scientific advisory board 25
Jun 21, 2017: Relmada Therapeutics appoints new executive clinical advisor 26
Jun 15, 2017: Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors 27
Legal and Regulatory 28
May 18, 2017: Relmada Therapeutics Announces Settlement of Legal Action with Laidlaw & Company 28
Product News 29
01/24/2017: Relmada Therapeutics to Provide an Update on the Development Plan for LevoCap ER 29
Other Significant Developments 30
Apr 16, 2018: BioAdvance Commits $3.2M to Life Sciences Companies in First Six Months of FY 2018 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List Of Tables

List of Tables
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Relmada Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Relmada Therapeutics Acquires Global Rights for Dextromethadone 10
Camp Nine Raises USD11 Million in Venture Financing 11
Relmada Therapeutics Raises USD15 Million in Venture Financing 12
Relmada Therapeutics Raises US$8 Million In Series A Venture Financing 13
Relmada Raises US$0.2 Million In Venture Financing 14
Relmada Therapeutics Secures USD3 Million in Series A Funding Round 15
Relmada Therapeutics Raises USD15.2 Million in Private Placement of Shares upon Exercise of Warrants 16
Camp Nine Raises USD2 Million in Private Placement of Shares 17
Relmada Therapeutics to Raise USD6.8 Million in Private Placement of 7% Convertible Promissory Notes Due 2019 18
Camp Nine Acquires Relmada Therapeutics 20
Relmada Therapeutics Acquires Medeor 21
Relmada Therapeutics Inc, Key Competitors 22
Relmada Therapeutics Inc, Key Employees 23
Relmada Therapeutics Inc, Subsidiaries 24

List Of Figures

List of Figures
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Relmada Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

ANGLE Plc (ANGLE) is a medical diagnostic company that offers cancer diagnostics and foetal health products. The company develops products for use in rare cell diagnostics that enable early, accurate

View Report

US Physical Therapy Inc (USPh) operates outpatient physical and occupational therapy clinics that offer pre-and post-operative care. The company provides treatment for orthopedic-related disorders, preventative care, sports-related injuries, rehabilitation of

View Report

University of Copenhagen (UCPH) is a university and research institution that offers educational and research programs and services. The university services include graduate and undergraduate courses, research programs, masters programs,

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports